Status:
NOT_YET_RECRUITING
Capillary Blood Accuracy
Lead Sponsor:
Entia Ltd
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Entia is a health technology company that has developed a blood testing device called Entia Liberty, which analyses blood collected by a finger prick. Entia is sponsoring this research study to compar...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old at the time of study entry
- Patients undergoing systemic anti-cancer therapy (SACT)
- Patients capable of providing written informed consent
- Patients undergoing routine Full Blood Count (FBC) laboratory blood tests as part of the standard of care
- Additional inclusion criteria:
- Phase 1 (Longitudinal, low count data): Neutrophil Count ≤ 1.0 x109/L within 24 hours preceding consenting
- Phase 2 (Low count data): Neutrophil Count ≤ 1.5 x109/L within 24 hours preceding consenting
Exclusion
- History or current diagnosis of haematological malignancy
- Inadequate use and understanding of the English language, requiring a translator
Key Trial Info
Start Date :
November 4 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 3 2025
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT06544070
Start Date
November 4 2024
End Date
November 3 2025
Last Update
August 9 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.